Holen Sie sich die Stockscreener-App
12.44
2.39%
0.29
Handel nachbörslich:
12.43
-0.010
-0.08%
Schlusskurs vom Vortag:
$12.15
Offen:
$12.21
24-Stunden-Volumen:
1.67M
Relative Volume:
0.99
Marktkapitalisierung:
$3.91B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-18.28
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+7.52%
1M Leistung:
+17.91%
6M Leistung:
+73.74%
1J Leistung:
+48.45%
1-Tages-Spanne:
$12.15
$12.50
1-Wochen-Bereich:
$11.45
$12.50
52-Wochen-Spanne:
$6.685
$12.50
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.44 | 3.82B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
127.89 | 54.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.50 | 44.92B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.06B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.99 | 28.42B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
485.77 | 20.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal Pharmaceuticals stock hits 52-week high at $12.12 - Investing.com
Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs - AOL.com
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know - Finviz
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones index2025 Performance Recap & Stepwise Trade Execution Plans - newser.com
Unpacking Q3 Earnings: Amneal (NASDAQ:AMRX) In The Context Of Other Generic Pharmaceuticals Stocks - Markets Financial Content
Ted Nark Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Is Amneal Pharmaceuticals Inc. stock trading near support levelsTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
Amneal Pharmaceuticals Insider Sold Shares Worth $586,000, According to a Recent SEC Filing - MarketScreener
Multi asset correlation models including Amneal Pharmaceuticals Inc.Trade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Is Amneal Pharmaceuticals Inc. stock in correction or buying zoneWeekly Risk Report & AI Powered Market Entry Strategies - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum playQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - newser.com
How high can Amneal Pharmaceuticals Inc. stock goEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Is Amneal Pharmaceuticals Inc. stock oversold or undervaluedVolume Spike & Fast Exit Strategy with Risk Control - newser.com
Amneal gets FDA nod for Iohexol Injection - MSN
Real time breakdown of Amneal Pharmaceuticals Inc. stock performancePortfolio Update Summary & AI Enhanced Trading Signals - newser.com
Candlestick signals on Amneal Pharmaceuticals Inc. stock todayMarket Weekly Review & Weekly High Conviction Ideas - newser.com
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutPortfolio Performance Summary & Weekly High Return Stock Opportunities - newser.com
Why The Narrative Around Amneal Is Shifting Amid Analyst Revisions and Recent FDA Approvals - Yahoo Finance
Amneal Pharmaceuticals (AMRX): Valuation Perspective After FDA Greenlight for First Generic Omnipaque and Raised Guidance - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock By Investing.com - Investing.com Australia
FDA Approves First Generic Omnipaque: Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX) - Yahoo Finance
Amneal pharma exec Nikita Shah sells $1.57 million in stock - Investing.com India
What analyst consensus says on Amneal Pharmaceuticals Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
FDA approves Amneal’s generic iohexol injection for imaging procedures By Investing.com - Investing.com Australia
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point - simplywall.st
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)’s Price Target To $13 Following Q3 Earnings Beat - MSN
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat - Finviz
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.83%
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):